Search
A generous gift provides a major boost to translational research at MSK.
Physician-in-Chief Lisa M. DeAngelis joins healthcare experts during the AACR Virtual Meeting: COVID-19 and Cancer to discuss how to safely bring patients to the clinic so they can receive vital cancer screenings and care.
Scientists came to give talks and celebrate the achievements that the program has made under the leadership of Kathryn Anderson.
New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).
Learn about the breast cancer type called ductal carcinoma in situ (DCIS) and how doctors decide on the best treatment for each person.
While there has been remarkable progress in the number of people surviving with stage 4 cancer, MSK remains dedicated to research that will spur much needed advances.
Androgen deprivation therapy may depress testosterone for prolonged periods in older patients, or those who are on the treatment for more than six months, increasing the risk of associated adverse events, according to the results of our recent retrospective study.
An MSK clinical trial is helping Gail Goode overcome multiple myeloma and sheds new light on how cancer affects people of diverse ethnic backgrounds.
Un ensayo clínico de MSK está ayudando a Gail Goode a superar el mieloma múltiple y arroja nueva luz sobre cómo el cáncer afecta a personas de diversos orígenes étnicos.
Internationally recognized cancer biologist Joan Massagué has been named Director of the Sloan Kettering Institute. He was previously Chair of the Cancer Biology and Genetics Program at Memorial Sloan Kettering.